Cresco Labs, like many marijuana stocks, faces challenges like black-market competition, lack of financial services, and high taxes. Its stock price has dropped significantly, making it a poor investment. The legal status of marijuana in the U.S. adds to the uncertainty, with varying state laws complicating matters.

Despite lobbying efforts for federal legalization, the future remains uncertain for Cresco Labs. Revenue is declining, and profitability is elusive. While the company recently refinanced a credit facility and has cash on hand, its survival is in question until federal legalization occurs.

Investors should consider the risks before buying stock in Cresco Labs. The Motley Fool Stock Advisor team did not include it in their list of top 10 stocks. Their recommendations historically outperform the market, with significant returns on past picks like Netflix and Nvidia.

The Motley Fool’s Stock Advisor has a track record of significant returns compared to the S&P 500. Their latest top 10 list is available for members, offering insights into potential high-growth stocks. Past recommendations have resulted in substantial returns for investors, showcasing the value of their research and analysis.

Read more at Yahoo Finance: If You’d Invested $1,000 in CRLBF 5 Years Ago, Here’s How Much You’d Have Today